QC
ESLA icon

Quadrature Capital’s Estrella Immunopharma ESLA Stock Holding History

Quadrature Capital’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,781
Closed -$43.3K – 1525
2025
Q4 		$43.3K Buy
+27,781
New +$52.6K ﹤0.01% 1187

Other funds holding ESLA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Quadrature Capital's ESLA Position: Q1 2026 in Review

Quadrature Capital sold out of Estrella Immunopharma (ESLA) in Q1 2026, closing a stake of 27,781 shares — an estimated $43.3K sold.

Quadrature Capital first reported a position in ESLA in Q4 2025 and held it in 1 quarter. The position peaked at $43.3K in Q4 2025. 16 funds tracked by Wall St. Rank hold ESLA as of Q1 2026.

  • Quadrature Capital reported no remaining Estrella Immunopharma position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 27,781 Estrella Immunopharma shares in Q1 2026, an estimated $43.3K.
  • Quadrature Capital first reported a position in Estrella Immunopharma in Q4 2025 and held it in 1 quarter.
  • Quadrature Capital's Estrella Immunopharma position peaked at $43.3K in Q4 2025.
  • 16 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.